Article
Novel modalities in the treatment of patients with KRAS-mutated colorectal cancer.
Anti-cancer drugs - 1 Jun 2011
Dimou Anastasios, Syrigos Konstantinos, Saif Muhammad Wasif
Abstract excerpt
Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene are a well-described mechanism of resistance to monoclonal antibodies that target the epidermal growth factor receptor in patients with metastatic and nonoperable colorectal cancer. Treatment options in this population are limited to conventional chemotherapy regimens and antiangiogenesis compounds. Numerous strategies have been proposed in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
